Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced a poster presentation on the ongoing global Phase 3 AGENT clinical study in patients with metastatic colorectal cancer (mCRC). The poster will be presented at the 2019 European Society of Medical Oncology (ESMO ) Congress, which is being held from September 27 to October 1, 2019, in Barcelona, Spain.Details on the presentation are as follows: Title: Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-